PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

PMV’s mission is to improve the lives of those suffering from serious and life-threatening diseases by delivering innovative solutions that combine the power of science and technology.

PMV’s vision is to become the world’s leading biotechnology company by delivering impactful therapies that improve the life and health of patients around the world.

PMV Pharmaceuticals has been honored with numerous awards since its inception, including Best Performing Company of the Year, Best Research and Development Company of the Year, Best Biotech Company of the Year, Best Place to Work, and many more.